Kamada (NASDAQ:KMDA) Announces Earnings Results

Kamada (NASDAQ:KMDA) announced its quarterly earnings results on Wednesday. The biotechnology company reported $0.07 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.12 by ($0.05), FiscalAI reports. The company had revenue of $45.24 million during the quarter, compared to the consensus estimate of $46.72 million. Kamada had a net margin of 11.21% and a return on equity of 7.69%.

Here are the key takeaways from Kamada’s conference call:

• Kamada reiterated full-year 2026 guidance for $200 million-$205 million in revenue and $50 million-$53 million in adjusted EBITDA, saying the outlook is based on organic growth only and implies stronger results in the back half of the year.
• First-quarter revenue was $42.5 million, up 3% year over year, with growth driven mainly by KEDRAB and the distribution segment. A temporary shipment delay reduced Q1 revenue by about $2.4 million, but the order was already delivered in April.
• Management said demand remains strong for key products, especially KEDRAB, which is seeing increased end-user utilization in the U.S. and international markets, and VARIZIG, which is benefiting from product awareness and more chickenpox outbreaks.
• The company is expanding its distribution and biosimilars business, with two additional biosimilars expected to launch in Israel by late Q2/early Q3 and a target of roughly 45 products in the Israeli portfolio by year-end. Management also expects biosimilar sales could reach $15 million-$20 million annually over the next four to five years.
• Kamada said its newly FDA-approved San Antonio plasma center is cleared to begin commercial normal source plasma sales in the second half of 2026, and both the Houston and San Antonio centers are expected to reach planned capacity toward end-2027/early-2028. The company also noted it remains active on business development and M&A to add products and synergies.

Kamada Price Performance

Shares of KMDA traded up $0.16 during midday trading on Thursday, hitting $8.02. The stock had a trading volume of 68,051 shares, compared to its average volume of 48,621. Kamada has a 1 year low of $6.50 and a 1 year high of $9.35. The firm has a market cap of $461.23 million, a PE ratio of 22.91, a price-to-earnings-growth ratio of 0.61 and a beta of 0.86. The stock’s 50 day moving average is $8.43 and its 200 day moving average is $7.89.

Kamada Announces Dividend

The company also recently announced an annual dividend, which was paid on Tuesday, April 7th. Stockholders of record on Monday, March 23rd were paid a $0.25 dividend. The ex-dividend date of this dividend was Monday, March 23rd. This represents a dividend yield of 305.0%. Kamada’s dividend payout ratio is currently 54.29%.

Institutional Investors Weigh In On Kamada

Several hedge funds and other institutional investors have recently made changes to their positions in KMDA. Jane Street Group LLC purchased a new stake in shares of Kamada in the first quarter valued at $582,000. Goldman Sachs Group Inc. bought a new position in shares of Kamada in the first quarter worth about $497,000. Arrowstreet Capital Limited Partnership bought a new position in shares of Kamada in the second quarter worth about $472,000. Bank of America Corp DE grew its holdings in shares of Kamada by 201.0% in the third quarter. Bank of America Corp DE now owns 61,565 shares of the biotechnology company’s stock worth $427,000 after purchasing an additional 41,111 shares during the last quarter. Finally, Marshall Wace LLP grew its holdings in shares of Kamada by 25.9% in the fourth quarter. Marshall Wace LLP now owns 196,954 shares of the biotechnology company’s stock worth $1,390,000 after purchasing an additional 40,514 shares during the last quarter. Hedge funds and other institutional investors own 20.38% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms recently issued reports on KMDA. Wall Street Zen downgraded shares of Kamada from a “strong-buy” rating to a “buy” rating in a research note on Saturday, March 14th. Benchmark reaffirmed a “buy” rating on shares of Kamada in a research note on Thursday, March 12th. Stifel Nicolaus set a $11.00 price target on shares of Kamada in a research note on Wednesday, March 11th. Finally, Weiss Ratings reaffirmed a “buy (b-)” rating on shares of Kamada in a research note on Thursday, January 22nd. Three research analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, the company currently has an average rating of “Buy” and a consensus target price of $13.00.

Kamada Company Profile

Kamada Ltd. is a biopharmaceutical company headquartered in Israel that specializes in the development, manufacturing and commercialization of plasma‐derived protein therapeutics. The company focuses on treatments for rare and serious diseases, leveraging its proprietary fractionation and purification technologies to produce purified human proteins. Kamada’s product portfolio addresses critical therapeutic areas in immunology, hematology and pulmonology, where alternative treatment options may be limited.

Among Kamada’s marketed products is Glassia®, an alpha‐1 antitrypsin augmentation therapy approved by the U.S.